Enhancing FCPA and Anti- Corruption Compliance for Life Sciences

With the heavy pursuit of life sciences continuing to grow by regulators, it is imperative to be prepared to endure a possible investigation.

10-11 Sep 2014 at Hilton Garden Inn Washington DC Downtown, District of Columbia, United States

Pharmaceuticals/Drug Discovery, Management

Submit new post
Thank you for posting.
Share it:

People (1)

Show all

Our experienced team of dedicated professionals deliver top-level networking environments and provide new interactive dimensions in event management for the North American region.

• Keep abreast of global regulation reform: an update on BRIC country anti-bribery acts
• Dissect the GSK case: what outcomes can you anticipate integrating to your program?
• Proactively prepare response techniques for when an international investigation may strike
• Streamline third party due diligence and HCP oversight globally
• Strengthen controls surrounding foreign clinical trials
• Develop effective techniques for conducting an extraterritorial CRO audit
• Deploy a global training program throughout the extended enterprise
• Hear the latest developments in conducting fool proof monitoring and auditing
• Gain information on the latest enforcement trends to avoid non-compliance
• Operationalize the compliance program to follow business venture activities: M&A due diligence
• Incorporating data analytics: exploring complexities of internal or external investigations in the digital age
• Mitigate risks manifesting from marketing and sales distribution channel

From: September 10, 2014 00:00
To: September 11, 2014 23:59

Hilton Garden Inn Washington DC Downtown, 20005, District of Columbia, United States


Pharmaceuticals/Drug Discovery, Management

Contact email

Contact phone
+1 3125824273

External link

Organized by: